Results 31 to 40 of about 1,538,497 (307)
Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction
Рациональная фармакотерапия в кардиологии, 2021 Atrial fibrillation and renal dysfunction often coexist, each disorder may predispose to the other and contribute to worsening prognosis. Both atrial fibrillation and chronic kidney disease are associated with increased risk of stroke and thromboembolic ...
Z. D. Kobalava +2 more
doaj +1 more source
Canadian Medical Association Journal, 2012 These medications are approved for the prevention of venous thromboembolism after hip or knee replacement and the prevention of stroke in patients with nonvalvular atrial fibrillation. Rivaroxaban is also approved for the treatment of deep vein thrombosis in patients without symptomatic ...
Dongmei, Sun, Alejandro, Lazo-Langner
openaire +2 more sources
Reversal of direct oral anticoagulants
, 2017 Mosaad Almegren Department of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia Abstract: Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and direct thrombin inhibitors, are a ...
Almegren M
core +2 more sources
Consequences of oral antithrombotic use in patients with chronic kidney disease
Clinical and Translational Science, 2021 We assessed the risks of bleeding, acute kidney injury (AKI), and kidney failure associated with the prescription of antithrombotic agents (oral anticoagulants and/or antiplatelet agents) in patients with moderate‐to‐advanced chronic kidney disease (CKD).
Solène M. Laville +14 more
doaj +1 more source
Oral anticoagulants in the elderly [PDF]
British Journal of Haematology, 2003 Summary. Over a 1‐year period, 34 998 prothrombin time tests were performed on 2379 patients aged 40–89 years with a recommended target International Normalized Ratio (INR) value of 2·5. At least one INR value of ≥ 5 was found in 507/2379 patients (21·3%).
Paul, Froom, Ehud, Miron, Mira, Barak
openaire +2 more sources
Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2022 A post-COVID patient with a high D-dimer Value (>5000 IU) was posted for total knee replacement. She was on multiple anticoagulants including the novel oral anticoagulants that started to reduce thrombotic risk.
Balasubramaniam Gayathri +3 more
doaj +1 more source
Development of oral anticoagulants [PDF]
British Journal of Clinical Pharmacology, 2007 Warfarin has been the drug of choice for the prophylaxis and treatment of arterial and venous thrombotic disorders for over half a century [1]. It is the only oral anticoagulant currently approved for use in the US. Warfarin, a vitamin K antagonist, inhibits four vitamin K-dependent coagulation factors including prothrombin (factor II) and factors VII,
openaire +2 more sources
Use of New Oral Anticoagulants/ Direct Oral Anticoagulants in Malignant Patients [PDF]
Cureus, 2020 Vitamin K antagonists are being used in the last five decades as an effective anticoagulant. However, for the past few years, new oral anticoagulants (NOACs) have been introduced as newer anticoagulant agents, which are gradually replacing the previously used vitamin K antagonist.
Khan, Yusra +4 more
openaire +2 more sources
Bleeding on oral anticoagulants: overview of reversal strategies
, 2023 Oral anticoagulants (antivitamin K, direct oral anticoagulants) are routinely prescribed for the prevention or treatment of thromboembolic events, and many patients are now on long-term anticoagulant therapy.
Mauro Foletti +17 more
core +1 more source
, 2014 Helen Mani, Edelgard Lindhoff-LastJohann Wolfgang Goethe-University Hospital Frankfurt/Main, Department of Internal Medicine, Division of Haemostasis, Frankfurt, GermanyAbstract: Atrial fibrillation (AF) continues to be a leading cause of cerebrovascular
Lindhoff-Last E +3 more
core +1 more source